cnbc semaglutide India's obesity and diabetes drug market is on the verge of taking off. Semaglutide, the molecule behind Ozempic and Wegovy will go off patent this Saturday paving the way for low-cost generic drugs THE 'OZEMPIC' TRADE LIVE |

While tirzepatide shares some mechanisms with GLP-1 receptor agonists, it has not yet received FDA approval for cardiovascular risk reduction, and its specific cardiovascular outcomes data for weight management are still emerging

Vitamin C chemically reduces BH2 back into active BH4, effectively "recoupling" the eNOS enzyme and restoring its normal, healthy function

It is recommended to start with a low dose and gradually increase it to the desired level

The answer is YES

It's very exciting to have, especially since it's more of a noninvasive strategy compared to bariatric surgery, and a lot more patients will be open to it.